title: [The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].
abstract: The features of the new selective MAO-B inhibitor razagiline (azilect) are reviewed against the background of latest advances in the field of treatment of Parkinson's disease (PD). The authors present the results of treatment of 20 patients in the full-blown stage of disease (mean age of patients 61.4±7.0 years). One of the objectives was to study the effect of razagiline on speech disorders in PD. A battery of scales was used to assess the global efficacy of treatment and the effect of the drug on the groups of symptoms. The high symptomatic effect of the drug used as monotherapy in early stages and in the combination with levodopa drugs in the full-blown stages of disease was revealed. It has been concluded that razagiline has a neuroprotective effect and modifies the course of PD. It exerts an effect on axial symptoms of PD: reduces speech disorders, postural instability, frequency of freezing episodes, severity of pharmacological dyskinesias.
authors.forename: N V
authors.initials: NV
authors.lastname: Fedorova
authors.forename: F K
authors.initials: FK
authors.lastname: Tekaeva
authors.forename: M E
authors.initials: ME
authors.lastname: Bel'gusheva
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D013064:Speech Disorders / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline